959795-70-1

4-(4-(4-Methylpiperazin-1-yl)piperidin-1-yl)aniline acts as a reagent in the preparation of Gilteritinib derivatives as inhibitors of FLT3-Axl.

GENERAL METHOD: 1-methyl-4-(1-(4-nitrophenyl)piperidin-4-yl)piperazine (2.18 g, 6.52 mmol) was dissolved in ethanol (50 mL) and 10% palladium carbon (wet basis, 53% water; 600 mg) was added. The reaction mixture was stirred at room temperature and 1 atm hydrogen atmosphere for 8 hours. Upon completion of the reaction, the insoluble material was removed by Celite filtration and the filtrate was concentrated under vacuum to afford 4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]aniline (1.96 g, 99%) as a light purple solid.

[1] Chemical and Pharmaceutical Bulletin, 2018, vol. 66, # 3, p. 251 - 262
[2] Patent: US2009/318441, 2009, A1. Location in patent: Page/Page column 45
[3] European Journal of Medicinal Chemistry, 2019, p. 690 - 709